Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Harvard BioscienceHBIO | Open-market buy | 03/16 | 04/01 | 5,000 sh | $5.00 | $25,000 | +40.0% | |
Stephen J. DenelskyDirector | Harvard BioscienceHBIO | Open-market buy | 03/17 | 03/18 | 10,000 sh | $4.87 | $48,700 | +90.9% |
Harvard BioscienceHBIO | Open-market buy | 03/16–03/17 | 03/18 | 21,000 sh2 trades | $4.93avg. | $103,603.5 | +190.9% | |
John D. DukeCEO | Harvard BioscienceHBIO | Open-market buy | 03/16 | 03/17 | 5,000 sh | $5.01 | $25,050 | +5.0% |
Harvard BioscienceHBIO | Open-market buy | 24/06/13 | 24/06/14 | 10,000 sh | $2.91 | $29,100 | +0.3% | |
Harvard BioscienceHBIO | Open-market buy | 24/06/06 | 24/06/07 | 20,000 sh | $3.07 | $61,400 | +0.6% | |
Harvard BioscienceHBIO | Open-market buy | 23/08/17 | 23/08/21 | 25,000 sh | $4.38 | $109,500 | +0.9% | |
Harvard BioscienceHBIO | Open-market buy | 23/03/14–23/03/15 | 23/03/16 | 30,000 sh2 trades | $2.64avg. | $79,290.4 | +17.4% | |
Harvard BioscienceHBIO | Open-market buy | 23/03/14–23/03/15 | 23/03/15 | 40,000 sh2 trades | $2.64avg. | $105,400 | +1.4% |